A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dermatology Consulting Services, PLLC
• Collaborator: Ortho Dermatologics
• Treatments: Halobetasol; Tazarotene

Criteria

Inclusion Criteria:

• 1. Males or non-pregnant females 18+ years of age.2. Plaque type moderate to severe scalp psoriasis suitable for topical treatment.3. Subjects must be in general good health as determined from a medical history.4. Subjects must read and sign the informed consent form after the nature of the study has been fully explained.

Exclusion Criteria:

• 1. Subjects with known allergies or sensitivities to ingredients contained in the test products.2. Subjects with pustular or erythrodermic psoriasis.3. Subjects who are pregnant or nursing or planning to become pregnant during the course of the study.4. Subjects who are currently participating in any other clinical study (i.e., dermal patch, use tests, investigational drug or devices, etc.).5. Subjects viewed by the investigator as not being able to complete the study.6. Subjects using any type of lotion, medication, or other topical product to the scalp psoriasis within 2 weeks of study entry.